Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding OC biology has led to the development several targeted therapies, including antiangiogenic agents poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors endocrine therapy such as selective estrogen receptor down regulators are currently under development. In this artic...